Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + carboplatin + pemetrexed in elderly patients with advanced non-squamous non-small cell lung cancer
jRCTs051190095Phase 2Completed
- Start
- Apr 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab, carboplatin and pemetrexed in Non-small cell lung cancer (NS-NSCLC). Primary endpoint: overall response rate. Started Apr 2020; status: completed.
02
Drugs
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on jRCTs051190095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051190095.